Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunmax Biotechnology Co's Total Assets for the quarter that ended in Dec. 2025 was NT$2,123 Mil.
Warning Sign:
If a company builds assets at 20% a year, faster than its revenue growth rate of 16.7% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Sunmax Biotechnology Co's average Total Assets Growth Rate was -5.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 6.00% per year.
During the past 5 years, the average Total Assets Growth Rate was 20.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 28.70% per year.
During the past 13 years, Sunmax Biotechnology Co's highest 3-Year average Total Assets Growth Rate was 51.50%. The lowest was -9.60%. And the median was 14.25%.
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Sunmax Biotechnology Co's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Sunmax Biotechnology Co Total Assets Related Terms
Sunmax Biotechnology Co Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Sunmax Biotechnology Co's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunmax Biotechnology Co (ROCO:4728) has a Total Assets of NT$2,123 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Sunmax Biotechnology Co and its competitors.
Is Sunmax Biotechnology Co's Total Assets too high?
Sunmax Biotechnology Co's current Total Assets is NT$2,123 Mil. Overall, Sunmax Biotechnology Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunmax Biotechnology Co's Total Assets compare to VRTX and REGN?
Sunmax Biotechnology Co's Total Assets of NT$2,123 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Sunmax Biotechnology Co and its competitors. Sunmax Biotechnology Co's current Total Assets is NT$2,123 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunmax Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Sunmax Biotechnology Co (ROCO:4728) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$441.52, compared to a current price of NT$381.00 — trading 13.7% below its estimated fair value. The current Total Assets is NT$2,123 Mil. Sunmax Biotechnology Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Sunmax Biotechnology Co (ROCO:4728), the current Total Assets is NT$2,123 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunmax Biotechnology Co (ROCO:4728) Overvalued in 2026?
Based on GuruFocus' analysis, Sunmax Biotechnology Co stock appears to be undervalued.
The current stock price of NT$381.00 is trading 13.7% below its estimated GF Value™ of NT$441.52.
GuruFocus considers Sunmax Biotechnology Co to be Modestly Undervalued.
Key valuation signals for ROCO:4728:
Total Assets: NT$2,123 Mil
GF Value™: NT$441.52 vs. price of NT$381.00 (13.7% below fair value)
No single metric tells the full story. See the ROCO:4728 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunmax Biotechnology Co Ltd is a biomedical company in Taiwan. It is engaged in the development, manufacturing, and commercialization of Sunmax medical devices and bio-surgical products. Additionally, it also researches, develops, manufactures and sales biomedical material grade collagen and related products. The company's products include medical products, biomedical materials, and porcine collagen skin care products.
91GF Score
Get the complete analysis for ROCO:4728
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4728 has been successfully added to your 
